Tecnandina’s Ecuador Facility Receives ANVISA Certification

Pharmaceutical Technology Editors;

News

Article

PTSM: Pharmaceutical Technology Sourcing and Management

October 1, 2015

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-10-07-2015

Volume11

Issue 10

Tecnandina’s Ecuador Facility Receives ANVISA Certification

Author(s):

Pharmaceutical Technology Editors

The Grünenthal Group’s Tecnandina manufacturing plant in Ecuador has received the country’s first certification from the Regulatory Authority of Brazil.

The Grünenthal Group announced on Oct. 1, 2015 that its Tecnandina manufacturing plant in Ecuador has received certification from the Regulatory Authority of Brazil (ANVISA), making it the first production plant in Ecuador to receive ANVISA certification. The certification will allow the company to export pharmaceutical products to Brazil.

Tecnandina SA belongs to the Grünenthal Group, a research-based, pharmaceutical company headquartered in Aachen, Germany.taht offers contract manufacturing from five independent production plants throughout Europe and Latin America. The company manufactures and exports to 17 countries in Central and South America, Switzerland, and the Andean countries.

Source: Grünenthal Group

Articles in this issue

Cost Inhibits CMO Adoption of Single-Use Equipment

Low Temperature Needed for Complex Drug Candidates

FDA Plans Pilot Projects for Drug Supply Chain Security Act

Vetter Embarks on 300-Million Euro Manufacturing Expansion

Sterigenics International Adds Capacity

Tecnandina’s Ecuador Facility Receives ANVISA Certification

Hovione Expands Drug Substance Manufacturing

Piramal Introduces Proof of Concept Service for Next Wave of ADC Growth

Patheon Unveils New Brand Identity

FDA Releases Guidance on Generic-Drug Development

Kopcha Selected to Head FDA’s Quality Office

Cobra Biologics Announces Scale-Up Collaboration

ReposiTrak Announces Track and Trace Agreement

Process Improves the Bioavailability of Active Ingredients

EMD Millipore Provides Risk-Assessment Information for Raw Materials

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!